Close

More on GPRO

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+22.2% Growth)
- Ratings (1.7 Score)
- Holders
- Event Driven Deals

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (5/9/24)
- Activism (Short)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

GPRO Cash Flow Statement

Click line-items for a historical chart and %
Operating activities
Net income 22.46M
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 11.45M
Amortization of premiums on investments, net of accretion of discounts 2.04M
Stock-based compensation 6.15M
Excess tax benefit from employee stock-based compensation -1.25M
Deferred revenue 477K
Deferred income tax -245K
Gain on contingent consideration
Loss on disposal of property and equipment 52K
Changes in assets and liabilities:
Trade and other accounts receivable -8.12M
Inventories -3.51M
Prepaid expenses -4.06M
Other current assets 1.16M
Other long-term assets
Accounts payable 2.23M
Accrued salaries and employee benefits -7.73M
Other accrued expenses 4.57M
Income tax payable 5.9M
Other long-term liabilities -49K
Net cash provided by operating activities 31.73M
Investing activities
Proceeds from sales and maturities of marketable securities 144.23M
Purchases of marketable securities -127.12M
Purchases of property, plant and equipment -9.27M
Purchases of capitalized software -1.74M
Purchases of intangible assets, including licenses and manufacturing access fees -825K
Cash paid for investment in Pacific Biosciences
Cash paid for investment in Roka Biosciences
Other 408K
Net cash provided by investing activities 5.69M
Financing activities
Repurchase and retirement of common stock 0
Proceeds from issuance of common stock and employee stock purchase plan 14.23M
Repurchase and retirement of restricted stock for payment of taxes -1.12M
Excess tax benefit from employee stock-based compensation 1.25M
Borrowings, net 0
Net cash provided by (used in) financing activities 14.35M
Effect of exchange rate changes on cash and cash equivalents -21K
Net increase in cash and cash equivalents 51.75M
Cash and cash equivalents at the beginning of period 87.02M
Cash and cash equivalents at the end of period 138.77M